Vertex Pharmaceuticals to Buy Alpine Immune Sciences for $4.9 Billion

Apr 11, 2024 By MarketDepth

Biotechnology Breaking Business Headlines What's Hot

prescription pills pink

Vertex Pharmaceuticals (NASD:VRTX) bought Alpine Immune for $4.9 billion for an all cash offer to get access to Alpines kidney disease treatments.The offer is a significant upgrade to current market value of Alpine Immune Sciences as its a 67% premium to previous market close price.

Vertex Pharmaceuticals has a current market cap of $103B which is on par with market cap from the beginning of the year. As the company starts to expand its product offerings and use cash on hand to continue its growth.